B. Metzler seel. Sohn & Co. Holding AG Purchases New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 113,501 shares of the biopharmaceutical company's stock, valued at approximately $9,516,000.

Several other hedge funds have also recently modified their holdings of the company. Capital World Investors lifted its position in shares of Gilead Sciences by 1.4% during the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company's stock worth $6,189,435,000 after buying an additional 1,133,281 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares during the period. Legal & General Group Plc raised its holdings in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company's stock worth $714,421,000 after purchasing an additional 268,208 shares during the period. Finally, Pacer Advisors Inc. raised its holdings in shares of Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company's stock worth $541,310,000 after purchasing an additional 1,564,792 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 1.0 %

Gilead Sciences stock traded up $0.88 during mid-day trading on Wednesday, hitting $88.63. The company's stock had a trading volume of 4,553,040 shares, compared to its average volume of 7,105,782. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market cap of $110.46 billion, a price-to-earnings ratio of 984.78, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. The business has a 50 day moving average price of $87.15 and a 200-day moving average price of $76.52. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,947 shares of company stock worth $4,968,674. Company insiders own 0.29% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research reports. Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a "sector perform" rating in a report on Monday. Citigroup began coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a "buy" rating and a $125.00 price objective for the company. Evercore ISI upgraded shares of Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Finally, Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.